Open AccessSafety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease
Author(s) -
Stephen A. Harrison,
Seth Baum,
Nadege Gunn,
Ziad Younes,
Anita Kohli,
Rashmee Patil,
Margaret James Koziel,
Harinder Chera,
Jeff Zhao,
Manu V. Chakravarthy
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/ajg.0000000000001375
Subject(s) - medicine , nonalcoholic fatty liver disease , tolerability , placebo , gastroenterology , insulin resistance , type 2 diabetes , homeostatic model assessment , adverse effect , fatty liver , endocrinology , diabetes mellitus , pathology , insulin , disease , alternative medicine